Restless Legs Syndrome: When Your Legs Won't Let You Sleep — and What to Do About It

KIMS Neuroscience, Secunderabad, Hyderabad offers specialist RLS assessment — including a comprehensive iron status evaluation (with the RLS-specific ferritin threshold of 75 µg/L), full neurological examination to exclude mimicking conditions, and up-to-date treatment aligned with the 2024 AASM guidelines. For many Indian patients, iron deficiency is the primary cause of their RLS, and treating it correctly resolves the condition. We also manage augmentation in patients on dopamine agonists and offer supervised transitions to safer first-line treatments.

Restless Legs Syndrome is a well-established, internationally recognised neurological condition with clear diagnostic criteria and a defined pathophysiology involving the dopamine system and iron metabolism in the brain. It is not anxiety, though anxiety can worsen RLS. It is not poor circulation, though the symptoms can be confused. It is not imagined. It affects approximately 2% of adults in India and is one of the most common causes of chronic insomnia. Many patients are initially dismissed or misdiagnosed — receiving treatment for anxiety, depression, or vascular problems before the correct diagnosis of RLS is eventually made.

Yes — iron deficiency is one of the most common causes of RLS, and in India, where iron deficiency anaemia is widespread (particularly in women), this is especially relevant. The brain needs iron to produce and regulate dopamine — the neurotransmitter whose abnormal function drives RLS symptoms. Critically, for RLS purposes, the relevant threshold for low iron is a serum ferritin below 75 µg/L — higher than the anaemia threshold of 12–15 µg/L used in standard lab reports. Many patients have ferritin levels that a standard lab report labels normal but that are actually insufficient for normal brain dopamine function. At KIMS, we use the RLS-specific ferritin threshold, and iron supplementation is the first treatment when ferritin is below this level.

What you may be experiencing is a well-recognised complication called augmentation. With long-term dopamine agonist treatment (pramipexole, ropinirole), a significant proportion of patients develop augmentation — a paradoxical worsening of RLS where symptoms start earlier in the day, become more intense, and spread to more of the body. Higher doses bring less relief, and the pattern escalates. The 2024 American Academy of Sleep Medicine guidelines now recommend against dopamine agonists as first-line treatment specifically because of this risk. If you are on pramipexole or ropinirole and your symptoms are getting worse, please seek specialist review at KIMS Neuroscience, Hyderabad — do not increase the dose or stop abruptly. A supervised transition to a different treatment class is needed.

Primary (idiopathic) RLS has a significant genetic component — approximately 40–60% of people with primary RLS have a positive family history. Several gene variants have been associated with primary RLS, including BTBD9 and MEIS1. The inheritance pattern is complex — not a simple dominant or recessive pattern — and the severity varies between affected family members. Secondary RLS (caused by iron deficiency, kidney disease, or medications) is not inherited. If you have primary RLS, your children have a moderately increased lifetime risk of developing it, though not a certainty.

Yes — chronic sleep disruption is one of the most significant consequences of RLS. The symptoms are worst at night and during rest, precisely when the body needs to fall asleep. The cycle of lying down, experiencing the irresistible urge to move, getting up to walk, returning to bed, and repeating — night after night — produces severe, cumulative sleep deprivation. The resulting fatigue, poor concentration, mood changes, and reduced daily functioning are often attributed to depression or stress before the underlying RLS is identified. Treating the RLS treats the insomnia — the two are directly linked.

Yes — RLS is particularly common in the third trimester of pregnancy, affecting approximately 20–25% of pregnant women. It typically appears or worsens in the final weeks of pregnancy and usually resolves within days to weeks after delivery. The most likely causes are iron depletion and the hormonal changes of late pregnancy. Management in pregnancy is primarily through iron supplementation (checking ferritin and correcting deficiency) and lifestyle measures. Medication options are more limited in pregnancy, and the choice must be made carefully in consultation with both the neurologist and obstetrician. KIMS Neuroscience works in coordination with our obstetrics team for pregnant patients with RLS.

Several practical measures help reduce RLS severity. Avoiding caffeine (coffee, tea, cola) particularly in the afternoon and evening reduces symptom severity for many patients. Avoiding alcohol — which provides temporary initial relief but then significantly worsens RLS during the sleep phase — is strongly recommended. Moderate regular exercise during the day improves RLS severity, but very intense exercise close to bedtime may temporarily worsen symptoms. Warm leg baths, massage, and keeping the bedroom cool provide comfort. Reviewing all current medications for known RLS triggers — antidepressants, antihistamines, antipsychotics, metoclopramide — is important. And checking iron stores is the first clinical step: an iron-rich diet (red meat, legumes, dark leafy vegetables) and iron supplements can make a meaningful difference.